4 Reasons Social Security Is In Trouble - Will You Be, Too?
How to Spend Less and Still Feed Your Family Well
You're Probably Wrong on Your Data Use - and It Costs You
Can Apple Restore the Luster of the iPad?
SciClone Pharmaceuticals to Report Financial Results for the First Quarter 2014 on May 12th
Stonepine Capital reports 5.3% passive stake in SciClone
Aegis Capital Still Firm on SciClone Pharma (SCLN) Following Q4 Results; Zadaxin Opportunity Still Robust
SciClone Pharmaceuticals' CEO Discusses Q4 2013 Results
SciClone sees FY14 EPS 41c-47c, consensus 52c
SciClone Reports 2013 Financial Results and 2014 Outlook
SciClone reports Q4 EPS 8c, one estimate 15c
SciClone Pharmaceuticals to Report Financial Results for the Fourth Quarter and Full Year 2013 on March 12th
SciClone Appoints Charles Meng as General Counsel and Vice President of Compliance
No Impact Expected from Change in Auditor at SciClone Pharma (SCLN); China Looks Better